Low-dose ketamine, typically given at around 0.5 mg/kg intravenously, has become one of the most studied rapid-acting treatments for severe depression, acute suicidal ideation, and certain chronic pain conditions. Originally developed as an anesthetic in the 1960s, ketamine at sub-anesthetic doses produces measurable mood improvements within hours rather than the weeks that conventional antidepressants require. The clinical picture is more complex than that headline suggests, though, with meaningful questions about who benefits most, how long the effects last, what the side effects look like, and how the different forms of the drug compare.
How Low-Dose Ketamine Acts on the Brain
At full anesthetic doses, ketamine shuts down conscious awareness. At the much lower doses used therapeutically, it does something different. The drug blocks a specific receptor involved in excitatory signaling in the brain, and this blockade paradoxically triggers a burst of the neurotransmitter glutamate in the prefrontal cortex. Animal studies have shown that low doses increase glutamate outflow in the prefrontal cortex and, at slightly higher sub-anesthetic levels, also raise dopamine release in the same region.1Europe PMC / Journal of Neuroscience. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex This glutamate surge is thought to kick off a cascade of downstream effects, including the formation of new synaptic connections. Brain imaging in healthy volunteers given sub-anesthetic ketamine has confirmed that the drug reshapes functional connectivity patterns, reducing activity in certain frontal midline regions while increasing it in parietal areas.2PubMed Central. Ketamine effects on default mode network activity and vigilance: A randomized, placebo-controlled crossover simultaneous fMRI/EEG study These shifts in brain network activity are part of what makes ketamine’s antidepressant action so rapid compared to drugs that work through serotonin pathways.
Rapid Antidepressant Effects
The most thoroughly studied use of low-dose ketamine is for treatment-resistant depression, meaning depression that has not improved after multiple rounds of standard antidepressants. A systematic review of the evidence found that a single sub-anesthetic infusion produced significant clinical improvement in depressive symptoms within hours.3PubMed Central. The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review That speed is essentially unmatched among psychiatric treatments. Conventional antidepressants typically need four to six weeks to show full effects, and many patients with treatment-resistant depression have already cycled through several of those medications without adequate relief.
A single sub-anesthetic dose can induce rapid and sustained antidepressant effects, but “sustained” is relative.4PubMed Central. Mechanisms of ketamine action as an antidepressant The mood improvement from a single infusion often starts to fade within days to about a week, which is why repeated infusions and maintenance protocols have become a focus of clinical research.
Suicidal Ideation
Perhaps the most striking application of low-dose ketamine is its ability to reduce suicidal thoughts quickly. A meta-analysis pooling individual patient data found that ketamine reduced suicidal ideation within one day, with moderate-to-large effect sizes at every time point measured after a single dose. The reduction in suicidal thinking remained significant even after accounting for changes in overall depression severity, suggesting ketamine does something specific beyond just lifting mood.5PubMed Central. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis
A double-blind, placebo-controlled trial tested this in patients with severe suicidal ideation and found that about 63% of those receiving ketamine reached full remission of suicidal ideas by day three, compared to roughly 32% in the placebo group. The separation between groups appeared as early as 40 minutes after infusion and persisted over the three-day observation period.6BMJ. Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial Emergency department studies have also shown that a 0.5 mg/kg dose reduces suicidal ideation and somatic symptom burden within two hours, with improvements in mood lasting at least six hours.7PubMed Central. A feasibility study of low-dose ketamine for acute management of suicidal ideation For emergency clinicians trying to stabilize someone in acute crisis, that kind of speed matters enormously.
Chronic Pain
Low-dose ketamine has attracted interest as a pain management tool, particularly for neuropathic pain conditions that resist other treatments. A narrative review found that the strongest case for ketamine in chronic pain involves neuropathic conditions like chronic radiculopathy or low back pain that has not responded to standard analgesics. Ketamine also has a specific role in patients with opioid tolerance or opioid-induced hyperalgesia, where the drug can be especially valuable because it works through an entirely different mechanism than opioids.8PubMed Central. Narrative Review: Low-Dose Ketamine for Pain Management
The evidence here is less clean-cut than for depression. One study of outpatient intravenous ketamine infusions in patients with high opioid requirements found that the infusions did not improve long-term pain scores, and only a few patients managed to substantially reduce their opioid use.9Pain Physician. Opioid-Sparing Effect of Intravenous Outpatient Ketamine Infusions Appears Short-Lived in Chronic-Pain Patients with High Opioid Requirements The picture that emerges is that ketamine can be a useful add-on for certain chronic pain patients, but it is not a reliable long-term solution for everyone, and the patients most dependent on opioids may benefit the least.
Post-Traumatic Stress Disorder
PTSD is another area where ketamine has shown early promise. A randomized clinical trial comparing a single ketamine infusion to the sedative midazolam found that ketamine produced a significant and rapid reduction in PTSD symptom severity within 24 hours, and the effect held up even after adjusting for any simultaneous improvement in depressive symptoms.10JAMA Psychiatry. Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder: A Randomized Clinical Trial A subsequent trial of repeated ketamine infusions over two weeks showed more durable results: about 67% of participants in the ketamine group were treatment responders at two weeks, compared to 20% in the midazolam group.11PubMed. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder
A systematic review and meta-analysis confirmed statistically significant improvements on a standard PTSD measure by the end of treatment courses lasting one to four weeks, though it flagged high variability across studies.12PubMed Central. Effectiveness of Ketamine for the Treatment of Post-Traumatic Stress Disorder – A Systematic Review and Meta-Analysis The research base for PTSD is still smaller and more heterogeneous than for depression, so clinicians tend to view it as a promising but not yet fully established indication.
Obsessive-Compulsive Disorder
A handful of studies have tested ketamine in treatment-resistant OCD, and the results are intriguing if still preliminary. A double-blind crossover study found that reductions in OCD symptom scores after ketamine were greater than those after the active control, and the benefit appeared to build in a dose-related fashion. Improvements peaked at one to two hours and a separation in scores persisted out to a week.13PubMed Central. Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study Broader reviews have noted that ketamine appears promising for OCD as well as substance use disorders and eating disorders, but the overall evidence base consists of small studies.14PubMed Central. Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature
What a Session Feels Like
Dissociation is the most commonly discussed acute side effect of sub-anesthetic ketamine. During an infusion, patients often experience a feeling of detachment from their body or surroundings, altered perception of time, and sometimes vivid visual imagery. Clinicians routinely monitor these effects using structured rating scales.15PubMed. A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions One study that characterized these experiences in detail found that average dissociation scores were moderate, not extreme, and that the overall subjective experience tended to be positive. The most common themes patients described were meaningful or spiritual experiences, positive mood shifts, and an inherent sense of paradox about the experience itself.16PubMed Central. Acute Subjective Experiences of Intravenous Ketamine Therapy Among Medically Hospitalized Patients with Alcohol Use Disorder
These effects are transient, typically resolving within an hour or two after the infusion ends. Whether dissociation itself contributes to the therapeutic benefit or is simply a side effect remains debated among researchers. Some patients find the experience unsettling, and clinics generally prepare patients with clear expectations beforehand.
Cardiovascular Effects and Urological Concerns
Ketamine is a sympathomimetic, meaning it temporarily stimulates the cardiovascular system. Even at low doses, it tends to raise blood pressure and heart rate during and shortly after administration.17PubMed. Concurrent increases in brain electrical activity and intracranial blood flow velocity during low-dose ketamine anaesthesia These increases are transient and generally modest in healthy individuals, but they mean that uncontrolled high blood pressure, recent stroke, or unstable cardiovascular disease are typically considered contraindications. Clinics monitor vital signs throughout infusions for this reason.
A more nuanced concern involves the urinary tract. Recreational ketamine users who take large, frequent doses have high rates of bladder and kidney problems, with some studies reporting lower urinary tract symptoms in 44% to 77% of heavy recreational users. But a comprehensive review found that in therapeutic contexts — lower doses, less frequent administration, professional supervision — the picture looks very different. Across 27 studies of ketamine for psychiatric conditions, urological symptom rates in randomized controlled trials did not differ meaningfully between ketamine and comparison groups. The review found no convincing evidence of ketamine-caused urinary problems arising from standard therapeutic use.18PubMed. Ketamine-Associated Uropathy During Therapeutic and Nontherapeutic Use: Prevalence, Clinical Features, Mechanisms, and Strategies for Risk Reduction That said, higher doses, more frequent dosing, longer treatment duration, and oral administration (which produces more urinary metabolites) are all potential risk factors. For patients on long-term maintenance protocols, periodic urological monitoring is prudent.
Drug Interactions Worth Knowing About
If you are on benzodiazepines and considering ketamine treatment for depression, the interaction between these two drug classes is worth discussing with your prescriber. Multiple studies have found that concurrent benzodiazepine use can blunt ketamine’s antidepressant effects. Higher benzodiazepine doses predicted slower time to response, shorter duration of benefit, and in some analyses, outright nonresponse. One analysis found that benzodiazepine doses equivalent to 10 mg or more of diazepam after a ketamine infusion predicted nonresponse during the following week.19International Journal of Neuropsychopharmacology. Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review A separate naturalistic study of subcutaneous esketamine similarly found that concomitant benzodiazepine use was associated with higher depression scores across treatment weeks.20PubMed. Role of concomitant benzodiazepines, lithium, and lamotrigine in modulating the antidepressant effects of subcutaneous esketamine in patients with treatment-resistant depressive episodes Lamotrigine and lithium, by contrast, did not appear to interfere with ketamine’s antidepressant action in the available data.
Abuse Potential in Clinical Settings
Ketamine is a controlled substance, and its potential for misuse is well established in recreational contexts. The critical question for patients is whether therapeutic use leads to problematic drug-seeking behavior. A scoping review of preclinical and clinical evidence concluded that while ketamine’s abuse potential is clear in animal models, limited clinical data indicate that single or repeated administrations in professionally controlled settings did not result in misuse, dependence, or diversion in patients with treatment-resistant depression.21PubMed. The abuse liability of ketamine: A scoping review of preclinical and clinical studies Acute adverse effects under clinical supervision are generally short-lived, but the risk profile shifts considerably in unsupervised or high-dose settings.22PubMed Central. Treating addiction with an addictive drug: the ketamine paradox revisited The practical takeaway is that context matters enormously. Clinic-based infusions with medical monitoring are a very different risk environment from unsupervised at-home use or recreational dosing.
Cognitive effects are another area where the recreational and therapeutic contexts diverge sharply. Heavy recreational ketamine users show memory and executive function impairments, but a study of users who achieved abstinence found significant recovery in recall, processing speed, and cognitive flexibility within 12 weeks.23PubMed. Recovery of cognitive functioning following abstinence from ketamine No comparable cognitive harms have been demonstrated at the low doses and infrequent schedules used in clinical treatment, though long-term monitoring data remain limited.
Maintenance Treatment and Preventing Relapse
Because a single ketamine infusion wears off within days, a key clinical question is how to extend the benefit. Repeated infusion protocols typically involve an initial course of several infusions over one to two weeks, followed by less frequent maintenance sessions. A randomized controlled trial found that about 59% of patients met response criteria after a repeated infusion course, with a median of three infusions needed before achieving response. Weekly maintenance infusions then held those gains steady, with no further decline in depression scores during the maintenance phase.24PubMed. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial
A retrospective study tracking longer-term outcomes found that patients receiving maintenance infusions roughly once a month maintained their improvements, with depression scores not worsening over an average follow-up of about 250 days. Depending on how relapse was defined, the estimated relapse rate after one year was in the range of 21% to 36%, with the average time to a relapse episode sitting around six months but varying widely between individuals.25European Psychiatry. Long-term maintenance therapy with ketamine infusions for treatment-resistant depression: a retrospective chart review These numbers are encouraging for a population that by definition has not responded to other treatments, but they also make clear that ketamine is not a one-time fix.
Esketamine, Arketamine, and Racemic Ketamine
The ketamine molecule exists in two mirror-image forms. Esketamine (the S-form) is the version approved by the FDA as a nasal spray for treatment-resistant depression. Arketamine (the R-form) is the less-studied sibling. Standard clinical ketamine is racemic, meaning it contains equal parts of both. These are not interchangeable.
Esketamine is roughly three times more potent as an analgesic and about 1.5 times more potent as an anesthetic than arketamine.26PubMed Central. Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms But potency at the receptor level does not necessarily translate to superior antidepressant effects. Preclinical work suggests that arketamine may actually produce stronger and longer-lasting antidepressant effects than esketamine despite weaker receptor binding, and it appears to cause fewer dissociative and psychosis-like side effects and carry lower abuse liability.27The Journal of Clinical Psychiatry. Racemic Ketamine vs Esketamine in Treatment-Resistant Depression: The Overlooked Role of Arketamine This is an active area of research, and arketamine is being investigated in clinical trials. For now, clinicians have two practical options: generic intravenous racemic ketamine (used off-label) and the FDA-approved esketamine nasal spray, which must be administered in a certified healthcare setting with post-dose monitoring.
Routes of Administration
Intravenous infusion remains the most studied route for therapeutic ketamine, largely because it allows precise dosing and rapid onset. But sublingual (under the tongue) formulations have drawn attention for their convenience. A pharmacokinetic study found that sublingual ketamine has an absolute bioavailability of about 29%, with detectable plasma levels appearing within five minutes and peak concentrations reached in roughly 45 minutes.28Europe PMC. The absolute bioavailability of racemic ketamine from a novel sublingual formulation That 29% figure means you need a substantially higher sublingual dose to match what an IV infusion delivers to the bloodstream. Oral ketamine has even lower bioavailability and produces more urinary metabolites, which is relevant to the bladder concerns discussed earlier. Intramuscular injection and nasal spray (used for esketamine) fall between these extremes in terms of absorption and convenience.
Adding Psychotherapy to Ketamine
A natural question is whether pairing ketamine with psychotherapy produces better results than ketamine alone. The rationale is appealing: the neuroplasticity window that ketamine opens could make therapy sessions more productive. A systematic review found that ketamine-assisted psychotherapy was associated with reductions in depressive symptoms, with some improvements lasting up to six months.29PubMed Central. Effectiveness of ketamine-assisted psychotherapy as a treatment for treatment-resistant depression: a systematic review However, among the studies that included control groups, no significant differences emerged between the combination and control conditions. A separate study comparing ketamine alone to ketamine plus psychotherapy in a help-seeking sample found no additional benefit from adding psychotherapy during the acute treatment phase.30PubMed. Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample The evidence is far from settled — study designs vary widely and the psychotherapy protocols tested have been inconsistent. But for now, the data do not strongly support paying extra for concurrent therapy sessions specifically timed around infusions.
Ketamine in Children and Adolescents
Pediatric depression is hard to treat, and the standard medications carry their own risks in younger patients. A systematic review of ketamine use in pediatric depression found that the drug was associated with reduced depressive symptoms without severe adverse events across the available studies, which all used intravenous administration at 0.5 mg/kg (with one exception using much lower microdoses).31PubMed. Ketamine use in pediatric depression: A systematic review The review cautioned that all studies had small sample sizes, and no trials have tested non-IV routes in this age group. On the pain management side, a pilot trial suggested that adding low-dose ketamine to a standard pain regimen after surgery in children could allow up to an 81% reduction in morphine use without compromising pain control.32Open Access Indonesian Journal of Medical Reviews. Evaluation of Morphine-Sparing Efficacy with Low-Dose Ketamine in Pediatric Postoperative Pain: A Pilot Randomized Controlled Trial These are preliminary findings, and ketamine for pediatric psychiatric use remains firmly in the research phase rather than standard practice.
Predicting Who Will Respond
Not everyone responds to ketamine, and researchers are actively searching for biomarkers that could predict who will benefit before treatment begins. Work in this area spans brain imaging, electrical brain activity patterns, sleep and circadian rhythm markers, stress hormone levels, immune markers, and genetic factors.33PubMed Central. Neurobiological biomarkers of response to ketamine None of these biomarkers has yet reached the point of routine clinical use, but the goal is practical: identify patients who are biologically more likely to respond, so that treatment can be better targeted rather than trial-and-error. For now, the most reliable predictor of ketamine response is still the clinical one — patients with treatment-resistant depression who have failed multiple other medications tend to be the population where ketamine is tried, and roughly half to two-thirds of them show a meaningful response to a course of infusions.